CTRI/2019/04/018673暂停未知
A Randomized, Open Label, Multicenter, Two Treatment, Multiple Dose, Steady State, Parallel Group, Bioequivalence Study of Amphotericin B Liposome for Injection 50 mg / vial of Sun Pharmaceutical Industries Limited and AmBisome® (Amphotericin B) Liposome for Injection 50 mg / vial of Astellas Pharma US, Inc. under Fed Condition.
Sun Pharmaceutical Industries Ltd India0 个研究点目标入组 0 人开始时间: 待定最近更新:
试验速览
- 阶段
- 未知
- 状态
- 暂停
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Ba/be
入排标准
入选标准
- •Subjects must fulfill all of the following inclusion criteria to be eligible for participation in the study, unless otherwise specified.
- •1.Male and non-pregnant, non-lactating female subjects with 18 to 75 years (both inclusive) of age.
- •2.Immunocompetent subjects who need Amphotericin B treatment for no less than 5 days as part of his/her therapy for following disease condition:
- •a. Presence of amastigotes of leishmania on smears of bone marrow aspirate, or smears of splenic aspirate, or histology of liver, marrow, or spleen or presence of amastigotes (Leishmania Donovani bodies) detected by rK39 dipstick test, and
- •b. Clinical Symptoms of visceral Leishmaniasis (fever of over 2 weeks duration, weight loss and splenomegaly)
- •3. Subjects with life expectancy greater than or equal to 4 weeks.
- •4. Subject having sufficient venous access to permit administration of study drug.
- •5. Subjects must have clinically acceptable results from all the screening and check-in laboratory investigations.
- •6. Subject and/or LAR who can able to understand and provide written informed consent.
- •7. Able to comply with study requirements and assessments.
- •8. Subjects of child bearing potential practicing an acceptable method of birth control for the duration of the study as judged by the investigator(s) such as birth control pills (if taken for at least 3 months prior to receiving the study medication), progestin injection or implants, condom plus spermicide, diaphragm plus spermicide, IUD, or vaginal spermicidal suppository or abstinence from sexual activity.
- •Postmenopausal with spontaneous amenorrhea for at least past 12 months (in case of Postmenopausal with spontaneous amenorrhea for at least 6 months then serum FSH level > 40 mIU/ml.
- •Surgically sterile (subjects with bilateral tubal ligation / bilateral oophorectomy / hysterectomy)
排除标准
- •Subjects must not be enrolled in the study if they meet any one of the following criteria:
- •1. Subjects with allergy or significant history of hypersensitivity or idiosyncratic reactions to any drug or excipients.
- •2. Subject had moderate or severe liver disease which is defined as:
- •(a) Transaminase (SGOT/AST or SGPT/ALT) > 10 times upper limit of normal (ULN)
- •(b) Total bilirubin > 5 times ULN
- •(c) Alkaline phosphatase > 5 times ULN
- •3. Subjects with Serum Creatinine > 2 x upper limit of normal.
- •4. Subjects with potassium levels <= 3.0 mmol/L or mEq/L.
- •5. Subjects who require concomitant therapy with intravenous fat emulsions, such as total parental nutrition (TPN).
- •6. Subjects with Hemoglobin level < 6 gm%, neutrophils <750/ mm3 and platelets <50,000 / mm3
- •7. Subjects with splenectomy
- •8. Subjects with Post-kala-azar dermal leishmaniasis.
- •9. Subjects who are receiving corticosteroids and corticotropin (ACTH), digitalis glycosides, azoles, other nephrotoxic medications, skeletal muscle relaxants (e.g. tubocurarine) within 30 days prior to enrollment in the study.
- •10. Subjects who are currently receiving or received antineoplastic agents prior to enrollment in the study.
- •11. Subjects who require leukocyte transfusions while receiving Amphotericin B.
- •12. Subjects who have shown positive result in breath alcohol test and/or urine drug screening test prior to check in
- •13. Subjects with history of drug or substance abuse or dependence, history of alcoholism in the past 1 year prior to screening.
- •14. Subjects who have donated blood or loss of blood or plasma of one unit (about 450 mL whole blood or 220 mL plasma) in the previous 60 days.
- •15. Subjects with history of difficulty with donating blood or difficulty in accessibility of veins or intolerance to venipuncture.
- •16. Subjects with history of allergic response to heparin.
- •17. Subjects with positive hepatitis screen (includes subtypes B & C).
- •18. Subjects with positive test result for HIV antibody.
- •19. Subjects with positive test result for syphilis (RPR/VDRL).
- •20. Subjects with any clinically significant ECG findings.
- •21. Participation in any investigational drug study within 30 days prior to first dose of study drug
- •22. Subjects with history of or current clinically significant medical illness including (but not limited to) cardiovascular, pulmonary, hepatic, renal, hematological, gastrointestinal, endocrine, immunologic, dermatologic, musculoskeletal, neurological, or psychiatric disease or any other illness that, that the investigator considers should exclude the subject.
- •23. Subjects with any other medical condition or comorbid complication that, in the investigatorâ??s judgment, might increase the risk to the subject or decrease the chance of obtaining satisfactory data needed to achieve the objectives of the study.
研究者
相似试验
尚未招募
不适用
Bioequivalence Study of Two Formulations of Azathioprine USP 50 mg tablet in Adult Rheumatoid Arthritis Patients Under Fasting Condition.CTRI/2017/10/009982RPG Life Sciences Ltd
招募中
不适用
Two-treatment Bioequivalence Study of Paliperidone Palmitate in adult schizophrenic patientsCTRI/2022/02/040103Pharmathen SA
招募中
1 期
A Randomized, Open-Label, Multicenter, Two Treatment, Two Period, Two Sequence, Single Dose, Crossover Bioequivalence Study of Doxorubicin Hydrochloride Liposome Injection 2mg/mL (50 mg/m dose)CTRI/2021/12/038914Alembic Pharmaceuticals Limited
招募中
不适用
A clinical study to assess the comparative blood concentration of two anti-cancer drugs (test and marketed Paclitaxel) in patients with breast cancerCTRI/2018/08/015506Teva Pharmaceuticals USA
已完成
不适用
Bioequivalence study of clozapine in schizophrenic patientsCTRI/2014/04/004524Remedica Ltd24